Partial and nonresponders to OnabotulinumtoxinA can benefit from anti-CGRP monoclonal antibodies preventive treatment: a real-world evidence study - Alpuente, A; Gallardo, VJ; Caronna, E; Torres-Ferrús, M; Pozo-Rosich, P (Eur J Neurol, 2021)